Skip to content
Subscriber Only

Gilead’s Sovaldi Wins Backing of U.K. Health-Cost Regulator

Gilead Sciences Inc.’s hepatitis C drug Sovaldi won the backing of the U.K.’s health-cost regulator, paving the way for the treatment to be reimbursed by British taxpayers at a price of almost $700 a pill.

A standard 12-week course of Sovaldi will cost almost 35,000 pounds ($58,380), not including tax or the price of interferon and ribavirin, the immune-boosting therapies that may be taken alongside the drug, the National Institute for Health and Care Excellence said in a statement today.